Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 11
Submit an article Journal homepage
1,088
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States

Lori Mufflya Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USAView further author information
,
Christopher Youngb Astellas Pharma, Inc, Northbrook, IL, USAView further author information
,
Qi Fengb Astellas Pharma, Inc, Northbrook, IL, USAView further author information
,
David Nimkeb Astellas Pharma, Inc, Northbrook, IL, USAView further author information
&
Bhavik J. Pandyab Astellas Pharma, Inc, Northbrook, IL, USACorrespondence[email protected]
View further author information
Pages 1832-1839 | Received 09 Jan 2023, Accepted 05 Jul 2023, Published online: 24 Jul 2023

References

  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
  • American Cancer Society. Key statistics for acute myeloid leukemia (AML). Accessed October 17, 2022. Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html.
  • Anders B, Veltri L, Kanate AS, et al. Outcomes of six-dose high-dose cytarabine as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia. Adv Hematol. 2017;2017:6464972. doi:10.1155/2017/6464972
  • Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695. doi:10.3390/jcm4040665
  • National Comprehensive Cancer Network (NCCN). NCCN guidelines acute myeloid leukemia (Version 1.2022). Accessed December 14, 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
  • Forsythe A, Sandman K. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med. 2021;12:245–255. doi:10.2147/JBM.S279736
  • Kennedy VE, Keegan THM, Li Q, et al. Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: a population-based analysis in the modern era. Cancer. 2022;128(1):139–149. doi:10.1002/cncr.33873
  • Leisch M, Jansko B, Zaborsky N, et al. Next generation sequencing in AML-nn the way to becoming a new standard for treatment initiation and/or modulation? Cancers. 2019;11(2):252. doi:10.3390/cancers11020252
  • Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
  • De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.50
  • Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol. 2012;6:205–217. doi:10.4137/CMO.S7244
  • Talati C, Sweet K. Recently approved therapies in acute myeloid leukemia: a complex treatment landscape. Leuk Res. 2018;73:58–66. doi:10.1016/j.leukres.2018.09.001
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi:10.1056/NEJMoa1902688
  • Watson Health. IBM MarketScan research databases for life sciences researchers. Accessed December 10, 2021. Available from: https://www.ibm.com/products/marketscan-research-databases.
  • Grinblatt DL, Pandya BJ, Han W, et al. Real-world use of FLT3-TKIs in R/R FLT3-mutated AML in the United States. Blood. 2020;136(Supplement 1):24–25. doi:10.1182/blood-2020-136391
  • Jabbour E, Cortes J, Ravandi F, et al. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013;50(4):271–283. doi:10.1053/j.seminhematol.2013.09.006
  • Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. 2021;35(2):299–311. doi:10.1038/s41375-020-01069-1
  • Perl AE. The role of targeted therapy in the management of patients with AML. Hematology Am Soc Hematol Educ Program. 2017;2017(1):54–65. doi:10.1182/asheducation-2017.1.54
  • Chevallier P, Labopin M, Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia. 2011;25(6):939–944. doi:10.1038/leu.2011.25
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
  • Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology Am Soc Hematol Educ Program. 2019;2019(1):539–547. doi:10.1182/hematology.2019000058

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.